title: Inhibition of the casein-kinase-1-ε/δ/ prevents relapse-like alcohol drinking.
abstract: During the past decade, it has been shown that circadian clock genes have more than a simple circadian time-keeping role. Clock genes also modulate motivational processes and have been implicated in the development of psychiatric disorders such as drug addiction. Recent studies indicate that casein-kinase 1ε/δ (CK1ε/δ)--one of the components of the circadian molecular clockwork-might be involved in the etiology of addictive behavior. The present study was initiated to study the specific role of CK1ε/δ in alcohol relapse-like drinking using the 'Alcohol Deprivation Effect' model. The effect of CK1ε/δ inhibition was tested on alcohol consumption in long-term alcohol-drinking rats upon re-exposure to alcohol after deprivation using a four-bottle free-choice paradigm with water, 5%, 10%, and 20% ethanol solutions, as well as on saccharin preference in alcohol-naive rats. The inhibition of CK1ε/δ with systemic PF-670462 (0, 10, and 30 mg/kg) injections dose-dependently decreased, and at a higher dosage prevented the alcohol deprivation effect, as compared with vehicle-treated rats. The impact of the treatment was further characterized using nonlinear regression analyses on the daily profiles of drinking and locomotor activity. We reveal that CK1ε/δ inhibition blunted the high daytime alcohol intake typically observed upon alcohol re-exposure, and induced a phase shift of locomotor activity toward daytime. Only the highest dose of PF-670462 shifted the saccharin intake daily rhythm toward daytime during treatment, and decreased saccharin preference after treatment. Our data suggest that CK1 inhibitors may be candidates for drug treatment development for alcoholism.
authors.affiliation: Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany. stephanie.perreau-lenz@zi-mannheim.de
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Perreau-Lenz
authors.forename: Valentina
authors.initials: V
authors.lastname: Vengeliene
authors.forename: Hamid R
authors.initials: HR
authors.lastname: Noori
authors.forename: Emilio V
authors.initials: EV
authors.lastname: Merlo-Pich
authors.forename: Mauro A
authors.initials: MA
authors.lastname: Corsi
authors.forename: Corrado
authors.initials: C
authors.lastname: Corti
authors.forename: Rainer
authors.initials: R
authors.lastname: Spanagel
mesh_terms: D000428:Alcohol Drinking / Q000188:drug therapy / Q000378:metabolism*; D000437:Alcoholism / Q000188:drug therapy / Q000201:enzymology; D000818:Animals; D048149:Casein Kinase 1 epsilon / Q000037:antagonists & inhibitors* / Q000502:physiology; D048148:Casein Kinase Idelta / Q000037:antagonists & inhibitors* / Q000502:physiology; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D055502:Secondary Prevention
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C522839:PF-670462; D048149:Casein Kinase 1 epsilon; D048148:Casein Kinase Idelta